期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

^(18)F-FDG PET/CT在弥漫性大B细胞淋巴瘤诊治中临床应用 被引量：1

CLINICAL APPLICATION OF ^(18)F-FDG PET/CT SCANNING IN DIFFUSED LARGE B-CELL LYMPHOMA
下载PDF
导出
摘要 目的探讨18F-FDG PET/CT对弥漫性大B细胞淋巴瘤(DLBCL)诊断、分期和治疗后评估的临床意义。方法对48例初诊DLBCL病人进行临床评价及18F-FDG PET/CT检查。结果18F-FDG PET/CT对初诊DLBCL病人的诊断灵敏度为98%(47/48);18F-FDG PET/CT分期与临床分期的一致性为92%(44/48),4例病人的分期结果不一致。18F-FDG PET/CT监测复发或微小残留病的敏感率高于临床评价。结论18F-FDG PET/CT对DLBCL的诊断、分期和疗效评估具有重要价值。 Objective To investigate the significance of ^18F-FDG PET/CT scaning in the diagnosis and staging of diffused large B-cell lymphoma （DLBCL） and its post treatment assessment. Methods Clinical evaluation and ^18F-FDG PET/CT scanning were done in 48 patients with initial diagnosis of DLBCL. Results The sensitivity of ^18F-FDG PET/CT in the patients was 98% （47/48）. Consistency of the clinical staging with the staging by ^18F-FDG PET/CT was 92%（44/48）. The sensitivity of detecting relapse or minimal residual lymphoma by ^18F-FDG PET/CT was higher than those by clinical evaluation. Conclusion ^18F- FDG PET/CT scanning plays an important role in the diagnosis, staging and prediction of the prognosis of DLBCL.
作者 史春雷 黄梅娟 王玲 李颖 袁成录
机构地区 青岛市中心医院血液科
出处 《齐鲁医学杂志》 2010年第2期130-131,134,共3页 Medical Journal of Qilu
关键词 正电子发射断层显像术 淋巴瘤 B细胞 诊断 治疗 positron-emission tomography lymphoma, B-cell diagnosis therapy
分类号 R733.41 [医药卫生—肿瘤] R814 [医药卫生—影像医学与核医学]
  • 相关文献

参考文献11

  • 1KAZAMA T, FARIA S C, VARAVITHYA V, et al. FDG PET in the evaluation of treatment for lymphoma:clinical usefulness and pitfals[J]. Radiographics, 2005,25(1) :191-207.
  • 2HARRIS N L, JAFFE E S, DIEBOLD J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting-Airlie House, Virginia, November 1997 [J].J Clin Oncol, 1999,17:3835-3849.
  • 3FREUDENBERG L S, ANTOCH G, SCHUTT P, et al. FDG-PET/CT in restaging of patients with lymphoma [J]. Eur Jnucl Med Mol Imaging, 2004,31(3) : 325-329.
  • 4王艳丽,崔新建.PET-CT在肺癌诊断及分期中的应用进展[J].齐鲁医学杂志,2009,24(1):90-91. 被引量：9
  • 5RODRIGUEZ M. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma[J].Acta Radiol, 1998,417(Suppl) : 1-36.
  • 6MOOG F, BANGERTER M, DIEDERICHS C G, et al. Extranodal malignant lymphoma:deteetion with FDG PET versus CT[J]. Radiology, 1998,206:475-481.
  • 7GROSS B H, GLAZER G M, ORRINGER M B, et al. Bronchogenic carcinoma metastatic to normal-sized lymphnodes:frequeney and significance[J]. Radiology, 1988,166 : 71-74.
  • 8CASTELLINO R A. Imaging techniques for staging abdominal Hudgkin' s disease[J]. Cancer Treat Rep, 1982,66 : 697-700.
  • 9叶任高，陆再英.内科学[M].5版．北京：人民卫生出版社,2002：258—260
  • 10SPAEPEN K, STROOBANTS S, DUPONT P, et al. Prognostic value of positron emission tomography with fluorine-18 fluorodeoxyglueose (18F-FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: 18 F-FDG PET a valid alternative to conventional diagnostic methods[J]. J Clin Oncol, 2001, 19:414-419.

二级参考文献12

  • 1林吉征,孙德宝,李颖端,李绍科,杨学东,路晓东.CT动态增强扫描对肺内孤立性小结节的鉴别诊断价值[J].青岛大学医学院学报,2006,42(4):312-314. 被引量：5
  • 2SWENSEN S J, VIGGIANO R W, MIDTHUN D E, et al. Lung nodule enhancement at CT: multieenter study[J]. Radiology, 2000,214(1) :73-80.
  • 3SHON I H, O'DOHERTY M J, MAISEY M N, et al. Positron emission tomography in lung cancer [J] .Semin Nucl Ued, 2002,32(4):240-271.
  • 4PRAUER H W, WEBER W A, ROMER W, et al. Controlled prospective study of positron emission tomography using the glucose analogue [18f] fluorodeoxyglucose in the evaluation of pulmonary nodules[J]. Br J Surg, 1998,85(11) : 1506-1511.
  • 5GOULD M K, MACLEAN C C, KUSCHNER W G, et al. Accuracy of positron emission tomography for diagnosis of pul monary nodules and mass lesions[J]. JAMA, 2001,285 (8) 914-924.
  • 6GOERRES G W, KAMEL E, SEIFERT B, et al. Accuracy of image coregistration of pulmonary lesions in patients with nonsmall cell lung cancer using 8n integrated PET/CT system[J], J Nucl Med, 2002,43(11) : 1469-1475.
  • 7SHIG S S, LEE K S, KIM Q T, et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging[J]. Radiology, 2005, 106(3): 1011-1019.
  • 8LARDINOIS D, WEDER W, HANY T F, et al. Staging of non-small cell lung cancer with integrated positron emission tomography and computed tomography[J]. N Engl J Med, 2003,348 (25): 2500-2507.
  • 9HALPERN B S, SCHIEPERS C, WEBER W A, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/ CT, and software image fusion[J]. Chest, 2005, 128(4): 2289-2297.
  • 10ANTOCH G, STATTAUS J, NEMAT AT, et al. Non-small cell lung cancer:dual modality PET/CT in preoperative staging [J]. Radiology, 2003,229(2):526-533.

共引文献118

同被引文献11

  • 1SCHUHMACHER C, GRETSCHEL S, LORDICK F, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954[J]. J Clin Oncoi, 2010,28(35) :5210.
  • 2HYUN H C, KIMJ W, HAN K H, et al. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer[J]. Gynecologic Ontology, 2011, 120(2):270-274.
  • 3ZHU D, MA T, NIU Z, et al. Prognostic significance of metabolic parameters measured by 18 F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer[J]. Lung Cancer (Amsterdam, Netherlands), 2011,73(3) :332-337.
  • 4OTT K, FINK U, BECKER K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging., results of a prospective trial[J]. J Clin Oncol, 2003,21(24): 4604-4610.
  • 5BECKER K, MUELLER J D, SCHULMACHER C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy[J]. Cancer, 2003, 98(7) :1521-1530.
  • 6OTT K, WEBER W A, LORDICK F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocareinomas of the esophagogastric junction[J]. J Clin Oneol, 2006 24(29) :4692-4698.
  • 7LORDICK F, OTT K, KRAUSE B J, et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial[J]. Lancet Oneol, 2007,8(9) :797-805.
  • 8VALLBOHMER D, HOLSCHER A H, SCHNEIDER P M, et al. ^18 F-fluorodeoxyglueose-positron emission tomography for the assessment of histopathologie response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer [J]. J Surg Oneol, 2010,102(2):135-140.
  • 9OTT K, HERRMANN K, LORDICK F, et al. Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study[J]. Clin Cancer Res, 2008,14(7) : 2012-2018.
  • 10LEE S M, KIM S H, LEE J M, et al. Usefulness of CT volumerry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer [J]. Abdom Imaging, 2009,34(4) :430-440.

引证文献1

二级引证文献3

齐鲁医学杂志
2010年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部